other material
confidence high
sentiment neutral
materiality 0.65
SAB Biotherapeutics raises $67.154M in Series A-1 Preferred; restructures warrant tranches
SAB Biotherapeutics, Inc.
- Initially issued 7,500 Series A-1 Preferred shares for $7.5M on Oct 2, 2023.
- Exercised Tranche A warrants: 59,654 additional shares for $59.654M by Nov 14.
- Investors assumed 16,269 unexercised warrants; received new Tranche B and C warrants.
- Outstanding now: 42,846 Tranche B warrants ($42.846M) and 107,115 Tranche C warrants ($107.115M).
- Unexercised Tranche A warrants and remaining Tranche B/C warrants cancelled.